CN105658203B - 含有大环内酯类抗菌剂的纳米微粒的水性悬浮剂 - Google Patents

含有大环内酯类抗菌剂的纳米微粒的水性悬浮剂 Download PDF

Info

Publication number
CN105658203B
CN105658203B CN201480058606.9A CN201480058606A CN105658203B CN 105658203 B CN105658203 B CN 105658203B CN 201480058606 A CN201480058606 A CN 201480058606A CN 105658203 B CN105658203 B CN 105658203B
Authority
CN
China
Prior art keywords
particle size
clarithromycin
aqueous
agent
macrolide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480058606.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN105658203A (zh
Inventor
多田贵广
加贺美和宏
横田志朗
菊池健太
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tai Xin Pharmaceutical Co Ltd
Original Assignee
Activus Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Activus Pharma Co Ltd filed Critical Activus Pharma Co Ltd
Publication of CN105658203A publication Critical patent/CN105658203A/zh
Application granted granted Critical
Publication of CN105658203B publication Critical patent/CN105658203B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201480058606.9A 2013-11-08 2014-11-07 含有大环内酯类抗菌剂的纳米微粒的水性悬浮剂 Active CN105658203B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013231796 2013-11-08
JP2013-231796 2013-11-08
PCT/JP2014/005603 WO2015068397A1 (ja) 2013-11-08 2014-11-07 マクロライド系抗菌剤のナノ微粒子を含有する水性懸濁液剤

Publications (2)

Publication Number Publication Date
CN105658203A CN105658203A (zh) 2016-06-08
CN105658203B true CN105658203B (zh) 2021-03-16

Family

ID=53041191

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480058606.9A Active CN105658203B (zh) 2013-11-08 2014-11-07 含有大环内酯类抗菌剂的纳米微粒的水性悬浮剂

Country Status (16)

Country Link
US (1) US10792248B2 (https=)
EP (1) EP3067045B1 (https=)
JP (1) JP6407882B2 (https=)
KR (2) KR20160079781A (https=)
CN (1) CN105658203B (https=)
AU (1) AU2014345193C1 (https=)
BR (1) BR112016010358B1 (https=)
CA (1) CA2929361C (https=)
ES (1) ES3003920T3 (https=)
IL (1) IL245406B (https=)
MX (1) MX2016005764A (https=)
PL (1) PL3067045T3 (https=)
PT (1) PT3067045T (https=)
RU (1) RU2707748C2 (https=)
TW (3) TW201521785A (https=)
WO (1) WO2015068397A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3067045T3 (pl) * 2013-11-08 2025-04-07 Activus Pharma Co., Ltd. Preparat wodnej zawiesiny zawierający nanocząstki makrolidowego środka przeciwbakteryjnego
CN114040782A (zh) 2019-04-30 2022-02-11 威斯康星州医药大学股份有限公司 跨鼓膜递送平台及其用途
CN113484436B (zh) * 2021-07-06 2022-07-12 云南中烟工业有限责任公司 同时测定抑菌纸张中五种禁限用物质含量的方法及其用途
US20230226541A1 (en) * 2022-01-18 2023-07-20 Hollister Incorporated Fluid absorption test tube
WO2023229667A1 (en) * 2022-05-24 2023-11-30 The Cleveland Clinic Foundation Topical angiotensin ii receptor blockers (arbs) for treating eye conditions
US20240009124A1 (en) * 2022-07-05 2024-01-11 Primera Compounding, LLC Ophthalmic Suspension Base having a Micro-fluidized Positively Charged Nanoparticle
CN116686841B (zh) * 2023-06-07 2024-07-19 丽珠集团新北江制药股份有限公司 一种含有多烯烃大环内酯类物质的液态组合物的制备方法
WO2024121651A1 (en) * 2023-11-10 2024-06-13 Amiri ِAmir Ali A liquid herbal antibiotic and a powder herbal antibiotic containing a herbal antibacterial formulation
CN121338014B (zh) * 2025-12-16 2026-03-27 山东齐都药业有限公司 罗红霉素制剂及其制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5098606A (en) * 1989-11-20 1992-03-24 Shiseido Company Ltd. Emulsified composition
CN1172428A (zh) * 1994-11-11 1998-02-04 美达克医疗专用制剂股份有限公司 作为具有增大的饱和溶解度和溶解速度系统形式的用于药物施用的药用毫微悬浮液
JP2007119456A (ja) * 2005-09-30 2007-05-17 Toyama Chem Co Ltd 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
CN101299993A (zh) * 2005-11-04 2008-11-05 伊士曼化工公司 用于给药难溶的药学活性剂的羧烷基纤维素酯
CN101636150A (zh) * 2007-04-06 2010-01-27 株式会社活效制药 微粉碎化有机化合物粒子的制造方法
US20100048498A1 (en) * 2004-12-21 2010-02-25 Johnson Barbara A Stable non-dihydrate azithromycin oral suspensions
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
EP2335686A1 (en) * 2009-12-21 2011-06-22 LEK Pharmaceuticals d.d. An aqueous intravenous nanosuspension with reduced adverse effects
WO2013168437A1 (ja) * 2012-05-11 2013-11-14 株式会社アクティバスファーマ 有機化合物ナノ粉体、その製造方法ならびに懸濁液

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2577742B2 (ja) * 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
AU630469B2 (en) 1989-05-26 1992-10-29 Abbott Laboratories Injectable clarithromycin composition
US5085864A (en) 1989-10-30 1992-02-04 Abbott Laboratories Injectable formulation for lipophilic drugs
AU6461090A (en) 1989-10-30 1991-05-02 Abbott Laboratories Injectable formulation for lipophilic drugs
US7205279B2 (en) * 1995-10-25 2007-04-17 Novartis Ag Pharmaceutical compositions
CA2279259A1 (en) * 1997-02-04 1998-08-06 Abbott Laboratories Pain reducing parenteral liposome formulation
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
WO2002015878A1 (fr) 2000-08-25 2002-02-28 Senju Pharmaceutical Co., Ltd. Preparations en suspension aqueuse
EP2283864A1 (en) 2002-07-16 2011-02-16 Elan Pharma International Ltd. Liquid dosage compositions fo stable nanoparticulate active agents
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
JP2009500356A (ja) 2005-07-07 2009-01-08 エラン ファーマ インターナショナル リミテッド ナノ粒子クラリスロマイシン製剤
HUE031951T2 (en) 2006-10-10 2017-08-28 Jina Pharmaceuticals Inc Aqueous systems for lipid-based drug compounds; preparations, processes and their use
US20080160043A1 (en) * 2007-07-16 2008-07-03 Kim Moo-Sung Preparation method of beta-glucan from schizophyllum commune and composition for external application comprising the same
JP5946990B2 (ja) * 2007-08-29 2016-07-06 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 化粧品及び医薬品使用のための精油を含有する糖系界面活性剤マイクロエマルジョン
AU2009271129B2 (en) 2008-07-14 2013-10-10 Otonomy, Inc. Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
PL3067045T3 (pl) * 2013-11-08 2025-04-07 Activus Pharma Co., Ltd. Preparat wodnej zawiesiny zawierający nanocząstki makrolidowego środka przeciwbakteryjnego

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5098606A (en) * 1989-11-20 1992-03-24 Shiseido Company Ltd. Emulsified composition
CN1172428A (zh) * 1994-11-11 1998-02-04 美达克医疗专用制剂股份有限公司 作为具有增大的饱和溶解度和溶解速度系统形式的用于药物施用的药用毫微悬浮液
US20100048498A1 (en) * 2004-12-21 2010-02-25 Johnson Barbara A Stable non-dihydrate azithromycin oral suspensions
JP2007119456A (ja) * 2005-09-30 2007-05-17 Toyama Chem Co Ltd 難溶性薬物のナノ微粒子を含有する水性懸濁液剤
CN101299993A (zh) * 2005-11-04 2008-11-05 伊士曼化工公司 用于给药难溶的药学活性剂的羧烷基纤维素酯
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
CN101636150A (zh) * 2007-04-06 2010-01-27 株式会社活效制药 微粉碎化有机化合物粒子的制造方法
EP2335686A1 (en) * 2009-12-21 2011-06-22 LEK Pharmaceuticals d.d. An aqueous intravenous nanosuspension with reduced adverse effects
WO2013168437A1 (ja) * 2012-05-11 2013-11-14 株式会社アクティバスファーマ 有機化合物ナノ粉体、その製造方法ならびに懸濁液

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Anti-bacterial performance of azithromycin nanoparticles as colloidal drug delivery system against different gram-negative and gram-positive bacteria;Morteza Azhdarzadeh等;《Advanced Pharmaceutical Bulletin》;20120215;第2卷(第1期);第18页右栏第2段、第19页左栏第2段倒数第10-12行、图2 *
FORMULATION & PROCESS DEVELOPMENT OF AZITHROMYCIN OPHTHALMIC NANOSUSPENSION;RASHESH K KOTECHA等;《International Journal of Pharmacy and Pharmaceutical Sciences》;20131031;第5卷(第4期);摘要、第490页右栏Preparation of nanosuspension、第493页左栏Particle size and polydispersity index、表4 *

Also Published As

Publication number Publication date
WO2015068397A1 (ja) 2015-05-14
EP3067045A1 (en) 2016-09-14
RU2016122544A (ru) 2017-12-13
CN105658203A (zh) 2016-06-08
AU2014345193B2 (en) 2020-03-05
TW201828923A (zh) 2018-08-16
JPWO2015068397A1 (ja) 2017-03-09
BR112016010358B1 (pt) 2022-07-26
KR20210054068A (ko) 2021-05-12
US10792248B2 (en) 2020-10-06
PL3067045T3 (pl) 2025-04-07
IL245406B (en) 2021-03-25
TWI691341B (zh) 2020-04-21
IL245406A0 (en) 2016-06-30
EP3067045B1 (en) 2024-12-04
MX2016005764A (es) 2017-01-05
CA2929361C (en) 2022-05-31
EP3067045A4 (en) 2016-11-16
ES3003920T3 (en) 2025-03-11
TW201521785A (zh) 2015-06-16
AU2014345193A1 (en) 2016-06-02
AU2014345193C1 (en) 2020-09-10
PT3067045T (pt) 2025-02-13
CA2929361A1 (en) 2015-05-14
US20160271057A1 (en) 2016-09-22
RU2016122544A3 (https=) 2018-05-29
BR112016010358A2 (https=) 2017-08-08
RU2707748C2 (ru) 2019-11-29
KR20160079781A (ko) 2016-07-06
KR102345084B1 (ko) 2021-12-29
JP6407882B2 (ja) 2018-10-17
TWI747209B (zh) 2021-11-21
TW202027726A (zh) 2020-08-01

Similar Documents

Publication Publication Date Title
CN105658203B (zh) 含有大环内酯类抗菌剂的纳米微粒的水性悬浮剂
US11376262B2 (en) Method of treating an inflammatory or infectious disease
TW202444380A (zh) 治療白內障手術併發症之方法
KR20260005238A (ko) 백내장 수술의 수술 합병증을 치료하는 방법
BR112017024000B1 (pt) Suspensão aquosa contendo nano partículas de glucocorticosteroide

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20250829

Address after: China Taiwan Taipei City Songshan District Fuxing North Road 57th Floor 8th Floor No. 6/8F-6

Patentee after: Tai Xin Pharmaceutical Co., Ltd.

Country or region after: Taiwan, China

Address before: Chiba Prefecture, Japan

Patentee before: ACTIVUS PHARMA Co.,Ltd.

Country or region before: Japan

TR01 Transfer of patent right